174 results about "Vaccine antigen" patented technology

The invention discloses a broad-spectrum monoclonal antibody for resisting porcine epidemic diarrhea virus S protein and application of the broad-spectrum monoclonal antibody. Specifically, firstly, two monoclonal antibodies GC33D8-1 and GC33A4-3 which have broad-spectrum binding characteristics with the porcine epidemic diarrhea virus S protein are obtained, the GC33D8-1 antibody has good universality and can have strong affinity with different strains, and the GC33A4-3 antibody can be bound for 3 times. Secondly, the two monoclonal antibodies are respectively used as a capture antibody and a detection antibody, a double-antibody sandwich ELISA method is established, and the double-antibody sandwich ELISA method is applied to PEDV vaccine S protein quantification, has better parallelism compared with other antibodies, and can be widely applied to detection of different strains. The method can be used for detecting semi-finished products and finished products, can be used for process establishment and optimization of porcine epidemic diarrhea virus vaccine antigens, vaccine quality evaluation and stability monitoring, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, and solves the problems that broad-spectrum detection cannot be carried out at present and an S protein ELISA method only can be used for qualitative judgment.

The invention provides a construction method and application of a high-efficiency expression system based on a Seali forest virus replicon. The method comprises the following steps: constructing a saRNA system for expressing a reporter gene; constructing to obtain replicase providing plasmids in the taRNA system; constructing to obtain an antigen providing plasmid in the taRNA system; the method comprises the following steps: respectively linearizing pSFV-CMV-T7-X, pSFV-CMV-T7-TR-X and pSFV-CMV-T7-replicase, and then carrying out in vitro transcription to prepare mRNA (Messenger Ribonucleic Acid); transfecting the prepared mRNA into a host eukaryotic cell for expression according to a certain proportion to obtain an antigen protein; and detecting the antigen protein to evaluate the expression efficiency of the saRNA and taRNA system based on the SFV replicon. According to the self-amplification DNA and RNA vaccine based on the virus replicon, the development period can be shortened, and the vaccine antigen can be expressed at a high level.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention discloses a method for detecting the content of monosaccharide components in bacterial capsular polysaccharide or a conjugate thereof, and belongs to the field of biological product detection. Taking pneumococcus as an example, different hydrolysis methods are adopted for different serotypes of capsular polysaccharides, connected glucosidic bonds are broken through hydrolysis, released monosaccharide components and 1-phenyl-3-methyl-5-pyrazolone are subjected to derivatization under the alkaline condition to generate derivatives with ultraviolet absorption, and then the capsular polysaccharides with different serotypes are obtained. And then detecting the composition and the content of each monosaccharide generated by polysaccharide hydrolysis through liquid chromatography. According to the method, each monosaccharide component can be quickly and effectively hydrolyzed, meanwhile, various polysaccharides with different structural characteristics can be separated and detected by adopting a derivatization method, whether the monosaccharide composition of each serotype polysaccharide accords with a theoretical structure or not can be qualitatively analyzed, and the content of each monosaccharide component can be quantitatively determined to calculate the content of the polysaccharides; and a better technical support is provided for quality control of the antigen component capsular polysaccharide of the bacterial vaccine.

The invention relates to the technical field of animal vaccines, and discloses an animal recombinant castration vaccine and a preparation method and application thereof, the animal recombinant castration vaccine comprises an animal castration vaccine antigen and an adjuvant, and the content of the animal castration vaccine antigen in the vaccine is 0.5-1 mg / mL. A gel type vaccine is prepared by adopting an animal castration vaccine antigen with an amino acid sequence as shown in SEQ ID No.2-4, and testis growth and development of rats are obviously inhibited after the rats are immunized. The animal castration vaccine antigen is also used for preparing vaccines in three dosage forms, namely an emulsion type vaccine, an aluminum salt type vaccine and a gel type vaccine, after the three vaccines are used for immunizing rats, the anti-GnRH antibody titer in the rats is obviously increased, the testosterone concentration is reduced (Plt; 0.05), and the testis growth and development are inhibited. The three dosage forms of vaccines all have good immune castration effect, and can be applied to castration or estrus inhibition of pets and economic animals in the future.

The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.

The invention discloses a monoclonal antibody and application thereof in quantitative detection of porcine epidemic diarrhea virus, and belongs to the technical field of biological detection. The preparation method comprises the following steps: firstly, obtaining two monoclonal antibodies GC44F3-1 and GC32C11-5 which specifically react with S protein of the porcine epidemic diarrhea virus; secondly, establishing a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) method by taking the two monoclonal antibodies as a coating antibody and a detection antibody respectively, and applying the double-antibody sandwich ELISA method to PEDV (Porcine Epidemic Diarrhea Virus) vaccine S protein quantification; the method can be used for detecting semi-finished products and finished products, can be used for process establishment, optimization, vaccine quality evaluation and stability monitoring of porcine epidemic diarrhea virus vaccine antigens, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, is high in detection flux and high in speed, solves the problem that TCID50 cannot meet vaccine quality evaluation at present, and has a good application prospect. The defect that the existing S protein ELISA method can only be used for qualitative judgment is overcome. The monoclonal antibody can also be used for blocking ELISA, capturing ELISA, indirect ELISA, competitive ELISA and a reagent for detecting the porcine epidemic diarrhea virus through a colloidal gold test strip.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.